Hereditary Angioedema (HAE) Therapeutics Market Analysis

Hereditary Angioedema Therapeutics Market Analysis

Based on the treatment type, the market is classified into C1 esterase inhibitors, bradykinin B2 receptor antagonist, kallikrein inhibitor, and other treatment types. The C1 esterase inhibitors segment dominated the market with revenue of USD 1.8 billion in 2023.
 

• Increased awareness and understanding of Hereditary Angioedema (HAE) among healthcare professionals and the public have led to earlier diagnoses and treatments. This has boosted the demand for C1 esterase inhibitors, the primary treatment for acute HAE attacks, thereby contributing to the market's growth.
   
• Moreover, C1 esterase inhibitors are recognized for their safety and effectiveness as targeted therapies. The preference for these specific treatments over broader options is driving their increased demand, which boosts market growth.
   
• In addition, the growing use of C1 esterase inhibitors for long-term prevention in HAE patients has significantly boosted this segment. The shift from on-demand treatment to preventive care is a major factor in this trend, further driving market growth.
   

Based on the route of administration, the hereditary angioedema therapeutics market is segmented into oral and parenteral. The parenteral segment dominated the market with market share of 68.5% in 2023.
 

• Innovations in parenteral delivery systems, such as autoinjectors and needle-free devices, have made self-administration of HAE therapies easier and less painful. These advancements have increased patient compliance and made parenteral therapies more appealing, driving market growth.
   
• Additionally, new parenteral therapies, such as monoclonal antibodies and plasma-derived C1 esterase inhibitors, have expanded treatment options for HAE. These therapies, which require parenteral administration, have driven the segment's growth due to their improved efficacy and targeted action, further fuelling the market growth for parenteral formulations.
   

Based on the age group, the global hereditary angioedema therapeutics market is segmented into pediatric, adult, and geriatric. The adult segment dominated the market and is expected to reach USD 5.1 billion by 2032.

• With advancements in diagnostic techniques and greater awareness of HAE among healthcare providers, more adults are being accurately diagnosed with the condition. This has led to a growing demand for therapies specifically tailored to adult patients.
   
• Additionally, adult patients are often more proactive in seeking treatment due to a better understanding of their condition. The growth of patient advocacy groups and educational campaigns targeting adults has also contributed to increased demand for HAE therapies in this segment.
   

Based on distribution channel, the hereditary angioedema therapeutics market is classified into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to exhibit 9.5% CAGR between 2024-2032.
 

• Hospital pharmacies specialize in managing and dispensing HAE therapies, such as C1 esterase inhibitors and bradykinin receptor antagonists. These treatments require specific storage, handling, and administration, which hospital pharmacies are well-equipped to provide. As a result, patients and healthcare providers prefer hospital pharmacies for HAE medications.
   
• Moreover, hospital pharmacies are essential to the healthcare system, especially in specialized institutions treating complex conditions like HAE. Advanced diagnostic tools, such as genetic testing for HAE, are available in hospitals to ensure timely and accurate diagnoses. This availability of appropriate therapeutic products in hospital pharmacies contributes to market growth.
   

In 2023, North America secured a substantial market share of 46.8% in the global hereditary angioedema therapeutics market and is expected to dominate throughout the forecast period.
 

• North America's strong R&D infrastructure, especially in the U.S., has enabled the rapid development and approval of new HAE therapies. The presence of leading pharmaceutical companies, academic institutions, and research organizations in the region has driven innovation and the introduction of advanced treatments to the market.
   
• Moreover, the expansion of specialized clinics and treatment centers for rare diseases like HAE in North America has improved patient access to care. These centers offer comprehensive services, including the latest therapies, which support market growth by ensuring patients receive timely and effective treatment.
   

Germany is set to experience the highest growth rate in the European market.
 

• Germany's robust healthcare system ensures that patients can access specialized treatments for rare diseases like HAE. Advanced facilities and expert healthcare professionals support the adoption of innovative therapies, which promotes market growth.
   
• Furthermore, the presence of many leading pharmaceutical companies and research institutions in Germany, focused on developing and commercializing hereditary angioedema (HAE) therapies, drives innovation and ensures that access to advanced treatments expands, thereby boosting market growth.
   

The Asia Pacific hereditary angioedema therapeutics market is expected to grow with a significant CAGR of 9.7% during the forecast period.
 

• The adoption of genetic testing in Asia-Pacific has seen a notable rise, which is crucial for the diagnosis of hereditary conditions like HAE. With improved genetic testing facilities and services, more patients are being accurately diagnosed, leading to a higher demand for targeted therapeutics.
   
• Moreover, the rise of local biopharmaceutical companies in countries like China and India has contributed to the market's growth. These companies are not only manufacturing but also developing new therapeutics that are more affordable, catering to the price-sensitive markets in the region, which further drives market growth.